• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Carestream prepares to unveil RIS/PACS pricing


Carestream prepares to unveil RIS/PACS pricingOther headlines:IDC revenues plummetMindray revenues skyrocketAmicas slips in 1Q

Carestream prepares to unveil RIS/PACS pricing

Carestream will focus on a new licensing structure for its latest generation of RIS/PACS at the Society for Imaging Informatics in Medicine meeting June 4 to 7. The new licensing approach offers tiered pricing tied to imaging volume. This approach allows for enterprise-wide use of the suite's advanced features for users of all sizes, according to the company. Key features of the Carestream PACS are a new PowerViewer workstation, new RIS for centralized enterprise-wide scheduling, and new "SuperPACS" architecture that creates a single user interface for disparate PACS.

IDC revenues plummet

A slowing economy cut gross revenues 58.8% at Imaging Dynamics Company for the quarter ended March 31 compared with the year-earlier period, but the digital radiography firm trimmed its losses by 40%. The company credited a reduced cash burn and better capital managing for the improved bottom line. Net loss for the quarter was $1.5 million compared with $2.5 million in the same quarter 2008. Net revenues were $2.6 million versus $6.4 million in 1Q 08.

Mindray revenues skyrocket

Net revenues boomed 53.5% for Mindray Medical International in the first quarter over the year-earlier period, but profits edged barely higher. Net income grew 1.2% to $25.3 million for the Chinese medical device maker, whose portfolio includes ultrasound scanners. Quarterly revenues rose to $134.2 million from $87.4 million. Ultrasound revenues increased 32.9% to $35.7 million, contributing 26.6% to the total net revenues in the first quarter 2009.

Amicas slips in 1Q

Revenues dropped 12% in the first quarter at Amicas, ballooning the PACS/IT company's operating losses 33% (to $1.6 million) compared with the year-earlier period. Total revenues in the quarter ended March 31 were $11.3 million compared with $12.8 million in 1Q 08. The $1.6 million operating loss included $549,000 in expenses related to the acquisition and integration of Emageon.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Nina Kottler, MD, MS
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2024 MJH Life Sciences

All rights reserved.